Short answer
Vertex Pharmaceuticals (VRTX) filed an 8-K current report with the SEC on September 1, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Jonathan Poole becomes CFO January 1, 2027, succeeding Charles Wagner, who remains Executive Vice President and COO.
Vertex Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Jonathan Poole becomes CFO January 1, 2027, succeeding Charles Wagner, who remains Executive Vice President and COO
- Poole brings Vertex finance experience since March 2020 and prior biotech CFO roles
- New CFO compensation: $750,000 base salary and 90% target annual bonus
- Change-of-control protections include severance, prorated bonus, equity acceleration, and benefits coverage up to 12 months
- Planned succession separates CFO and COO responsibilities, potentially sharpening financial leadership accountability
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vertex Pharmaceuticals 8-K filings
Get the next VRTX 8-K as it lands
Follow VRTX for push alerts, or ask the research agent what this filing means.